×îÐÂÏûÏ¢£º
¼òÌåÖÐÎÄ | English
Ê× Ò³ ¹«Ë¾¸Å¿ö ²úƷչʾ ÐÐÒµÓ¦Óà ¹«Ë¾ÐÂÎÅ ·þÎñÖÐÐÄ ÁªÏµÎÒÃÇ
  >>²úÆ·Óë·þÎñ
  >>ÐÐÒµÓ¦ÓÃ
  ²úÆ·ºÍ·þÎñ
  3D΢Á÷ÌåÆ÷¹ÙÄ£Äâϵͳ

3D΢Á÷ÌåÆ÷¹ÙÄ£Äâϵͳ

Ó¢¹ú PhysioMimix Organs-on-Chips

²úÆ·¼ò½é:


PhysioMimix™ÏµÍ³¿ÉÒÔÅàÑøÈËÌåϸ°û£¬Ê¹ÆäÄ£·ÂÈËÌåÆ÷¹ÙºÍ×éÖ¯µÄ½á¹¹ºÍ¹¦ÄÜ¡£ÔÊÐíµ¥Æ÷¹ÙºÍ¶àÆ÷¹ÙʵÑ飬ʵʱ¿ØÖÆÏ¸°ûÅàÑøÌõ¼þ£¬ÒÔÄ£ÄâÌåÄÚÉúÀíѧ¡£¿ÉÒÔ¿ìËÙ¡¢ÇáËɵش´½¨Èýά»îÐÔ×éÖ¯²¢×Ô¶¯¿ØÖÆÎ¢Á÷Ìå,ΪÐÅÏ¢·á¸»µÄ·ÖÎöÌṩ³¤ÆÚÊÕÒæÂÊϸ°ûµÄÅàÑø»ù´¡¡£

PhysioMimix™3D΢Á÷ÌåÆ÷¹ÙÄ£ÄâϵͳÖ÷ÒªÌØµã£º


PhysioMimix™½áºÏÁé»îµÄϸ°ûÀàÐͺÍÅàÑø¸ñʽ£¬Organ-on-ChipʵÏÖÒ»¸öÇ¿´óµÄµÄ¡¢Ò×ÓÚʹÓõŤ¾ß

¼òµ¥¡¢Áé»îµÄоƬÉÏÓÐÆ÷¹Ù×éÖ¯µÄÖÆ±¸

PhysioMimix™ÊÇÒ»ÖÖ¾ßÓпª·Åʽ°å¿é¼æÈÝÉÌÒµ²åÈë×éÖ¯Ö§¼ÜͬʱҲÊÇ×ÔÓÉÅàÑø-Ö§¼Ü,±ãÓÚÒÆ³ýºÍÖØÐ½ÓÈëµÄ¿ÉÑéÖ¤»ò¶¨ÖƵÄÄ£ÐÍϵͳ¡£

·ûºÏÄúµÄÑо¿ÐèÒªµÄʵÑéÉè¼Æ

ÈÝÒײ¥ÖÖ,¼ÓÒ©ºÍÈ¡ÑùµÄϸ°ûºÍÅàÑø»ùPhysioMimix™ÊÇ¿ª·Åʽ,MPSÔØÅÌ¡£Ã»ÓÐPDMS×é¼þ£¬¿ÉÒÔ¼õÉÙ·ÇÌØ¶¨µÄ°ó¶¨µÄ¸ÉÈÅ£¬´Ó¶øÔöÇ¿Äú¶Ô½á¹ûµÄÐÅÐÄ¡£

Ö§³Ö³¤ÆÚʵÑ飬×îµÍµÄÓû§Í¶Èë

×Ô¶¯»¯µÄ΢Á÷Ìå¼¼ÊõÒÔ¼°Æ÷¹Ù¼äºÍÆ÷¹ÙÄÚÁ÷¶¯ËٶȵÄÁé»îÐÔ£¬Ê¹Ï¸°ûÅàÑøÌõ¼þµÄ×ÝÏò¿ØÖÆ¡¢¶¯Ì¬ÉúÎï¹ý³ÌµÄÄ£ÄâºÍƽ̨ҩ¶¯Ñ§µÄ¿ØÖƳÉΪ¿ÉÄÜ¡£

ÄúµÄʵÑéϸ°ûºÍʵÑéÊҿռ䶼ÊDZ¦¹óµÄ

PhysioMimix™ÊÇÒ»¸ö×îÐÂÐÍ,µÍ¿Õ¼äÕ¼ÓõÄÒÇÆ÷¼æÈÝPhysioMimix™Ì×ÅàÑøÔØÆ¬£¬Ê¹µ¥¸öͶ×ʾͿÉÒÔ´ï³É³¤Ê±¼äµÄ¸ßÖÊÁ¿Êý¾Ý·á¸»µÄʵÑé¡£

Ó¦ÓÃÁìÓò£º


ÃâÒߣ¬Éñ¾­£¬´úлϵͳ°ÐÏòÒ©ÎïÑз¢

ÉúÎï±êÖ¾·¢ÏÖ

¸öÈË»¯Ò©ÎïÑз¢

¶¯ÎïʵÑéÌæ´ú·½°¸

ÔÚÅàÑøÃóÖÐÁÙ´²ÊµÑé

Ò©ÎÑ̲Ý£¬»¯×±Æ·£¬»¯Ñ§ÐÐÒµ¼à¹Ü²âÊÔ

PhysioMimix™ T1 Series –¹¤×÷Á÷³Ì


SEEDÖÖÖ²


•ÈκÎϸ°û¶¼ÄÜÇáËɵÄÖÖÖ²ÔÚ¿ª·ÅʽµÄÅàÑø°åÉÏ¡£

•¹ã·ºµÄÅàÑøÐÎʽѡÔñ£¬°üÀ¨ÉÌÒµÖ²ÈëÎÆ÷¹ÙÇÐÆ¬£¬3D»ùÖʺÍÄý½º£¬×éÖ¯ÌØÒìÐÔÖ§¼Ü£¬ÎÞÖ§¼ÜÅàÑø

•ÈÝÒ×¶¨ÖÆ»òÑé֤ϸ°û/×é֯ģÐ͵ļÓÔØÏµÍ³°üÀ¨MucilAir™, EpiSkin™ºÍ¸ü¶àÆäËûϵͳ

CULTUREÅàÑø


•¿É±à³ÌÓ¦ÓÃÁ÷Ìåѧ¡£Æ÷¹ÙÄÚÁ÷Á¿¿Éµ÷£¬ÓÅ»¯ÑõÆø£¬ÓªÑøºÍ»úеÁ¦

•¿É·½±ãµØÓÅ»¯¸÷Æ÷¹Ù¼äµÄÁ÷ËÙ£¬ÒÔʵÏÖ¾«È·µÄƽ̨ҩ¶¯Ñ§

•ý½é±ä»¯Ñ¸ËÙÇÒÈÝÒ×ʵÏÖ

DOSE¸øÒ©


•½éÈëÉúÎïÖÆ¼Á(ëÄ¡¢µ°°×ÖÊ)¡¢Ð¡·Ö×Ó¡¢¼¤ËصÈ

• »ùÒò±à¼­(CRISPR, Talen, ZFN)

•ÒýÈëÃâÒßϸ°û(Èçϸ°û¶¾ÐÔTϸ°û¡¢CAR-Tϸ°û¡¢NKϸ°ûµÈ)½øÐÐÃâÒß·ÖÎöºÍ¹Û²ì

•ÎÞPDMS×é¼þ£¬×î´óÏ޶ȼõÉÙ·ÇÌØ¶¨°ó¶¨¸ÉÈÅ

ANALYZE ·ÖÎö


•¼òµ¥µÄ(ÖØ¸´µÄ)½éÖÊÈ¡ÑùÓÃÓÚÉúÎï±êÖ¾Îï·ÖÎö(LC-MS, ELISA, multiplex)

•¿ÉÒÆ¶¯Ö§¼ÜÔÊÐí¶Ô΢×éÖ¯½øÐÐÈ«·½Î»µÄ·ÖÎö×éѧ·½·¨

•×é֯ģÄâ¿ÉÓÃÓÚ³ÉÏñ£¬ÒÔ¿ÉÊÓ»¯Ï¸°ûÐÎ̬¡¢Ï¸°ûÇ¨ÒÆºÍµ°°×±ê¼ÇÎﶨλ

¹æ¸ñ²ÎÊý£º


PhysioMimix™ T1 Controller ——¿ØÖÆÆ÷¿ÉÒÔ²¢ÐвÙ×÷¶à´ï12 MPS°å°²×°ÔÚ4¸öDocking Stations

PhysioMimix™ DS3 Docking Stati——Docking Stationͨ¹ýÒ»¸ùϸµçÀÂÁ¬½Óµ½¿ØÖÆÆ÷¡£³äµ±PhysioMimix MPSÇý¶¯³ÌÐòºÍ¿ØÖÆÆ÷Ö®¼äµÄ½Ó¿Ú

PhysioMimix™ MPSDriver——ÿ¸öMPSÇý¶¯Æ÷´îÅäÒ»¸öMPS°å

ÎÄÏ×Áбí


[Infectious disease] Ortega-Prieto AM et al. 3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection. Nat Commun. 2018 Feb; 9:pp-pp.

[Diabetes and NASH] Kostrzewski T et al. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(2): 204-215

[Oncology] Wheeler SE et al. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer 2014; 111(12): 2342-2350

[2-Organs] Dalrymple A et al. The characterisation of a human two Organ-on- a-Chip (lung-liver) system which has the potential to measure systemic responses in vitro. Poster presented at Society of Toxicology 57th Annual meeting; 2018 Mar 11-15: San Antonio, Texas.

[4/7/10-Organs] Edington et al. Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies. Sci Rep, 2018. IN PRESS[Drug Safety] Long TJ et al. Modeling Therapeutic Antibody-Small Molecule Drug- Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform. Drug Metab Dispos 2016; 44(12): 1940-1948

[Drug Metabolism] Vivares A et al. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica 2015; 45(1): 29-44

[Drug Metabolism] Tsamandouras N et al. Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System. J Pharmacol Exp Ther 2017; 360(1): 95-105

 

°æÈ¨ËùÓÐ Copyright (C) 2018-2020 ÉϺ£°£·Éµç×ӿƼ¼ÓÐÏÞ¹«Ë¾ All Rights Reserved »¦ICP±¸16036014ºÅ-2 ²úƷչʾ| ÐÐÒµÓ¦Óà | ·þÎñÖÐÐÄ | ÁªÏµÎÒÃÇ
¿­·¢ÊÖ»ú¿Í»§¶ËÏÂÔØ <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Ö©Öë´Ê>| <Îı¾Á´> <Îı¾Á´> <Îı¾Á´> <Îı¾Á´> <Îı¾Á´> <Îı¾Á´>